8-KRegulation FDExhibits & Filings

Guardant Health, Inc. 8-K Report, Regulation FD Disclosure (Jan 13, 2020)

Filed January 13, 2020For Securities:GH

Summary

Guardant Health, Inc. (GH) filed an 8-K on January 13, 2020, to disclose information that will be presented at upcoming investor conferences and forums. This filing primarily incorporates by reference a presentation slide deck, dated January 2020, which contains information relevant to investors. While the filing itself doesn't introduce new financial results or material operational changes, it signifies the company's proactive engagement with the investment community to share potentially updated strategic insights or business developments. Investors should review the attached Exhibit 99.1 for the specific details Guardant Health intends to communicate. This disclosure suggests the company is likely to discuss its progress, market positioning, or future outlook in areas related to its cancer detection technologies. As this information is being shared under Regulation FD, it's intended for broad public dissemination, making the accompanying presentation slides a crucial source of information for understanding the company's current messaging to the market.

Key Highlights

  • 1Guardant Health released an 8-K filing on January 13, 2020, to disseminate information via investor presentations.
  • 2The filing incorporates by reference a presentation slide deck dated January 2020 (Exhibit 99.1).
  • 3This 8-K is primarily a Regulation FD disclosure, meaning the content is for broad public release.
  • 4No new financial statements or material adverse events are detailed in the 8-K itself.
  • 5Investors are directed to the attached presentation slides for substantive information.
  • 6The disclosure indicates ongoing engagement with the investor community.
  • 7The content of the presentation likely covers company updates, strategy, or market insights.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly disclose information that Guardant Health representatives intend to present at investor conferences and other forums. It serves as a Regulation FD disclosure to ensure broad and fair dissemination of this information.

The specific information is contained within the presentation slides, dated January 2020, which are attached as Exhibit 99.1 to this Current Report on Form 8-K. This exhibit is incorporated by reference into the filing.

No, this 8-K filing does not include new financial statements or report any material adverse events. Its primary function is to provide the content of an upcoming investor presentation for public access.

This filing is significant because it provides investors with early access to the key messages and updates Guardant Health plans to share with the investment community. Investors should carefully review the accompanying presentation slides (Exhibit 99.1) for insights into the company's current focus, strategy, and market outlook.